Astrazeneca says Catalent deal shows importance of in-house capacity
In this article:
LONDON, Feb 8 (Reuters) - Astrazeneca on Thursday said the sale of contract drugmaker Catalent to the parent of Novo Nordisk this week demonstrates the importance of building an independent supply chain.
AstraZeneca is a client of Catalent for some of its drug manufacturing, but AstraZeneca is working to boost its in-house capacity to cut reliance on contract drugmakers, Chief Executive Pascal Soriot told reporters after the release of fourth-quarter results. (Reporting by Maggie Fick in London and Eva Mathews in Bengaluru Editing by David Goodman )
